Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of oral ferric maltol in iron deficiency anemia with LVAD-associated heart failure
2016-005101-39Phase 4Completed
- Sponsor
- Hannover Medical School
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric maltol in iron deficiency anemia (IDA) and heart failure (HF), sponsored by Hannover Medical School. Primary endpoint: Relative and absolute frequency of adverse events (AEs) and serious adverse events (SAEs). Started May 2018; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)heart failure (HF)
Beyond the preview
Go deeper on 2016-005101-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005101-39.